Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Saurabh Saha M.D., Ph.D. | CEO & Director | 1.04M | -- | 1976 |
| Dr. David M. Chao Ph.D. | Chief Administrative Officer | 710.3k | -- | 1968 |
| Mr. John J. Crowley CPA | CFO and Principal Financial & Accounting Officer | -- | -- | 1974 |
| Ms. Tia L. Bush | Chief Technology & Quality Officer | -- | -- | 1971 |
| Ms. Kristen K. Sheppard Esq., J.D. | Senior Vice President of Investor Relations & Corporate Communications | -- | -- | -- |
| Mr. Iqbal J. Hussain L.L.B. | General Counsel, Chief Compliance Officer & Corporate Secretary | -- | -- | 1981 |
| Ms. Karen M. Anderson | Chief People Officer | -- | -- | 1968 |
| Dr. Gregory M. Weinhoff M.B.A., M.D. | Chief Business Officer | 655k | -- | 1971 |
| Dr. Mario Alberto Accardi Ph.D. | President of the Orexin Program | -- | -- | -- |
| Dr. Ellie Im M.D. | Senior Vice President of Clinical Development & Oncology | -- | -- | -- |
Centessa Pharmaceuticals plc
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 76
Description
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available